PMID- 37051882
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230612
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 78
IP  - 6
DP  - 2023 Jun 1
TI  - Evaluation of the tolerance of ceftriaxone by subcutaneous route in patients >/=75 
      years old in geriatric departments: a prospective observational study.
PG  - 1495-1498
LID - 10.1093/jac/dkad115 [doi]
AB  - OBJECTIVES: The subcutaneous (SC) route provides an alternative to the IV or oral 
      route for drug administration in the elderly. The benefits of SC administration 
      have been proven for hydration but are still debated for antibiotics because 
      tolerance remains uncertain, especially in the frail geriatric population. Here, 
      we aimed to improve current knowledge concerning the tolerance profile of 
      ceftriaxone SC administration at both the systemic and cutaneous level, as well 
      as in terms of pain. PATIENTS AND METHODS: This was a prospective descriptive 
      study of SC ceftriaxone tolerance in a geriatric department. We included all 
      patients over 75 years of age who received a prescription for SC ceftriaxone in 
      our hospital over a 5 month period. METHODS: We evaluated the systemic and local 
      tolerance of SC ceftriaxone. Nurses were asked about their perceptions concerning 
      its use. RESULTS: Among 117 patients, 57% presented with pain and 60% with a mild 
      local adverse effect, such as the formation of oedema in one-third of patients, 
      induration or transient erythema. Finally, there were no serious local adverse 
      effects and two systemic adverse effects were observed (one diarrhoea and one 
      Clostridioides difficile colitis). Pain was mainly related to the skin breach and 
      oedema formation. CONCLUSIONS: We did not find any worrying signs concerning the 
      use of SC ceftriaxone but this study shows that its wide use must consider pain 
      management, which is often overlooked.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of British 
      Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Renoncourt, Thomas
AU  - Renoncourt T
AUID- ORCID: 0000-0001-7432-9587
AD  - Department of Geriatric Medicine, CHU Amiens-Picardie, University Hospital 
      Amiens-Picardie, 80054, Cedex 1, Amiens, France.
FAU - Dossoubadjiokila, Justine
AU  - Dossoubadjiokila J
AD  - Department of Geriatric Medicine, CHU Amiens-Picardie, University Hospital 
      Amiens-Picardie, 80054, Cedex 1, Amiens, France.
FAU - Mondet, Lisa
AU  - Mondet L
AD  - Department of Pharmacology, CHU Amiens-Picardie, Amiens, France.
FAU - Pecquet, Pauline-Eva
AU  - Pecquet PE
AD  - Department of Pharmacovigilance, CHU Amiens-Picardie, Amiens, France.
FAU - Bennouna, Nysrine
AU  - Bennouna N
AD  - Department of Geriatric Medicine, CHU Amiens-Picardie, University Hospital 
      Amiens-Picardie, 80054, Cedex 1, Amiens, France.
FAU - Gras-Champel, Valerie
AU  - Gras-Champel V
AD  - Department of Pharmacovigilance, CHU Amiens-Picardie, Amiens, France.
FAU - Bennis, Youssef
AU  - Bennis Y
AUID- ORCID: 0000-0002-0186-4797
AD  - Department of Pharmacology, CHU Amiens-Picardie, Amiens, France.
FAU - Bloch, Frederic
AU  - Bloch F
AD  - Department of Geriatric Medicine, CHU Amiens-Picardie, University Hospital 
      Amiens-Picardie, 80054, Cedex 1, Amiens, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 75J73V1629 (Ceftriaxone)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Ceftriaxone/adverse effects
MH  - Anti-Bacterial Agents/adverse effects
MH  - Injections, Subcutaneous
MH  - Prospective Studies
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Pain/drug therapy/chemically induced
EDAT- 2023/04/14 06:00
MHDA- 2023/06/02 06:42
CRDT- 2023/04/13 04:53
PHST- 2022/12/19 00:00 [received]
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/06/02 06:42 [medline]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/04/13 04:53 [entrez]
AID - 7116673 [pii]
AID - 10.1093/jac/dkad115 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2023 Jun 1;78(6):1495-1498. doi: 10.1093/jac/dkad115.